ANIX (Anixa Biosciences) ROCE %: -77.39% (As of Apr. 2026)

What is Anixa Biosciences ROCE %?

Anixa Biosciences ANIX -2.60% 27 ROCE % is -77.39% as of Apr. 2026. GuruFocus rates ANIX with a GF Score™ of 27/100. The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Anixa Biosciences's annualized ROCE % for the quarter that ended in Apr. 2026 was -77.39%.

Anixa Biosciences (NAS:ANIX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Anixa Biosciences ROCE % Related Terms

Anixa Biosciences ROCE % Historical Data

* Premium members only.

The historical data trend for Anixa Biosciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anixa Biosciences ROCE % Chart

Anixa Biosciences Annual Data

Trend

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Oct24

Oct25

ROCE %

Get a 7-Day Free Trial

-60.74

-43.80

-42.46

-64.96

-70.48

Anixa Biosciences Quarterly Data
	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25	Apr25	Jul25	Oct25	Jan26	Apr26
ROCE %	Get a 7-Day Free Trial															-75.08	-63.53	-77.47	-77.30	-77.39

27GF Score

Anixa Biosciences Inc ANIX

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Anixa Biosciences ROCE % Calculation

Anixa Biosciences's annualized ROCE % for the fiscal year that ended in Oct. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Oct. 2025 )		(A: Oct. 2024 )		(A: Oct. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Oct. 2025 )		(A: Oct. 2024 )		(A: Oct. 2025 )
	=	-11.701	/	( ( (21.591 - 2.5)	+	(16.08 - 1.967) )	/ 2 )
	=	-11.701	/	( (19.091	+	14.113)	/ 2 )
	=	-11.701	/	16.602
	=	-70.48 %

Anixa Biosciences's ROCE % of for the quarter that ended in Apr. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Apr. 2026 )		(Q: Jan. 2026 )		(Q: Apr. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Apr. 2026 )		(Q: Jan. 2026 )		(Q: Apr. 2026 )
	=	-10.588	/	( ( (15.233 - 1.236)	+	(14.865 - 1.501) )	/ 2 )
	=	-10.588	/	( ( 13.997	+	13.364 )	/ 2 )
	=	-10.588	/	13.6805
	=	-77.39 %

(1) Note: The EBIT data used here is four times the quarterly (Apr. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -77.39% mean?

Anixa Biosciences (ANIX) has a ROCE % of -77.39% as of Apr. 2026.

Is Anixa Biosciences' ROCE % too high?

Anixa Biosciences' current ROCE % is -77.39%. Overall, Anixa Biosciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.

How does Anixa Biosciences' ROCE % compare to PYPD and LONA?

Anixa Biosciences' ROCE % of -77.39% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Biotechnology company?

A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. Anixa Biosciences's current ROCE % is -77.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Anixa Biosciences stock overvalued right now?

Anixa Biosciences (ANIX) has a current ROCE % of -77.39%. The current ROCE % is -77.39%. Anixa Biosciences' overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Anixa Biosciences (ANIX), the current ROCE % is -77.39% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anixa Biosciences Business Description

Industry Healthcare Biotechnology

Comparable Companies PYPD LONA SGMO OKYO AARD ICCC TELO NRXS PTHS CUE VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges CY71:Germany

Address 3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118

Website https://www.anixa.com

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

27GF Score

Get the complete analysis for ANIX

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.64

Price

View ANIX Analysis

See ROCE % data for all stocks →